Crohn DiseaseEASE PAINNCT05913817
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
An observational study of Crohn Disease and Ulcerative Colitis, run by Jamp Pharma Corporation at 1 site in Canada.
Trial summary
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis
- What is being tested?
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Type of treatment
- Injection or infusion
- How many people
- 324 participants
- Where
- 1 siteCanada
- Study dates
- 9 Jan 2023to 25 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: To ensure a representative study population, any eligible patient that meets the inclusion/exclusion criteria should be invited to participate in this non-interventional study.
Who may be able to join
- Patient aged 18 years or older at the time of consent.
- Patient has been diagnosed with CD, UC, RA, AS, PsA, HS, or PsO for at least 6 months.
- Patient must be a current user of Humira® or another low-concentration adalimumab biosimilar, with treatment initiated at least 6 months prior to screening.
- One of the following:
- Treating physician is considering switching from Humira® to SIMLANDI™,
- Treating physician is considering switching from an adalimumab biosimilar (not Humira®) to SIMLANDI™.
Show all 12Show fewer
- Treating physician has switched from Humira® or Humira® biosimilar to SIMLANDI™ within the past 3 months.
- Patient must be willing to keep using the same type of injector when switching from their previous adalimumab treatment to SIMLANDI™:
- Pre-filled to pre-filled switch,
- Autoinjector to autoinjector switch.
- Access to commercial SIMLANDI™.
- Patient or patient's legal/authorized representative agrees to sign informed consent and participate in the study.
Who cannot join
- Patients previously treated with SIMLANDI™ or another high-concentration adalimumab biosimilar.
- Patients that, in the opinion of the investigator, have any condition that may impair their ability to participate in the study.
- Any current or history of any condition that, in the opinion of the investigator, participation in the study may increase the risk to the patient.
- Patients for whom treatment with adalimumab may be contraindicated (e.g., patients with demyelinating disorders).
- Patients with moderate to severe heart failure, as indicated by New York Heart Association (NYHA) class >= 3.
- Patients with severe infections such as sepsis, tuberculosis, or opportunistic infections.
Show all 12Show fewer
- Patients with history of recurrent infection or with underlying conditions which may predispose them to infections.
- Patients with known hypersensitivity to SIMLANDI™ or its excipients.
- Patients who are unable to secure reimbursement for SIMLANDI™.
- Patient anticipates not being available for follow-up assessments as required for adequate management.
- Active participation in or enrollment in an interventional trial.
- Patient or patient's legal/authorized representative cannot or will not sign informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
The phase IV study is an observational, pan-Canadian, multidisciplinary study aiming to enroll 600 patients across 50-70 sites across 3 different Therapeutic Areas (GI, Rheum, Derm).
Read the detailed description
The current phase 4 study seeks to assess the real-world injection experience, utilization, satisfaction, effectiveness, safety, and tolerability of treatment with AVT-02 (SIMLANDI™) in patients when switching from low-concentration adalimumab Humira® or another adalimumab biosimilar to high-concentration adalimumab SIMLANDI™ for the management of certain gastroenterological (IBD, including CD or UC); rheumatological (including RA, AS, or PsA); or dermatological conditions (including HS or PsO).
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis
- Being tested
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Keywords
- Injection Site Pain
- Medical subject headings
- Crohn Disease, Colitis, Ulcerative, Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Hidradenitis Suppurativa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AVT02 (Alvotech Biosimilar to Adalimumab)Biological
Also called Humira
Phase IV Study
| Study group | Role | What they receive |
|---|---|---|
| Adalimumab Reference Product to AVT-02 | Patients switching from the high-volume, low concentration, citrate containing Adalimumab reference product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar. Receives: Biological: AVT02 (Alvotech Biosimilar to Adalimumab) | |
| Other Adalimumab Biosimilar to AVT-02 | Patients switching from another high-volume, low concentration, citrate-containing or citrate-free Adalimumab biosimilar product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar. Receives: Biological: AVT02 (Alvotech Biosimilar to Adalimumab) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in injection site pain after the first dose of high-concentration adalimumab (AVT-02) as measured by the Visual Analog Scale (VAS); 2 weeks after Humira Injection (can be 1 week for certain indications such as HS).
Baseline injection site pain will be defined as the VAS score recorded during the last dose of the low-concentration adalimumab prior to switching to AVT-02.
Measured: At 2 Weeks
Secondary outcomes (8)
Change from baseline in injection site pain after every injection of the high-concentration adalimumab (AVT-02) as measured by VAS during the 180 days of the study.
Baseline injection site pain will be defined as the VAS score recorded during the last dose of the low-concentration adalimumab prior to switching to AVT-02.
Measured: At Every AVT-02 Injection up to 180 Days.
Patient perception of change in injection site pain (5-point Likert) after the first dose of high-concentration adalimumab (AVT-02) compared to Humira® or another low-concentration adalimumab biosimilar.
A five-point Likert scale of patient perception of change in injection site pain after the first dose of high-concentration adalimumab (AVT-02).
Measured: Once a month up to 180 Days.
Distribution of missed doses of AVT-02.
Adherence to treatment when switching from Humira® or another adalimumab biosimilar to AVT-02.
Measured: At Every AVT-02 Injection up to 180 Days.
Change from baseline in overall satisfaction with the injection (7-point Likert) during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02.
A seven-point Likert scale of patient satisfaction.
Measured: At Every AVT-02 Injection up to 180 Days.
Change from baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02.
A questionnaire assessing health-related quality of life covering five dimensions (mobility, ability to self-care, ability to undertake usual activities, pain/discomfort, and anxiety/depression) with five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems).
Measured: At days 30, 60, 90, 120, 150, and 180.
Change from baseline in physician disease assessment during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02
Asses the Physician Global Assessment (PGA) at baseline and at Day 180.
Measured: At Baseline and at Day 180.
Change from baseline in patient-reported disease assessment during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02
Asses the Patient Global Assessment of Disease Activity (PtGA) at baseline and at Day 180.
Measured: At Baseline and at Day 180.
Change from baseline in health care utilization during the 180 days of the study.
A questionnaire assessing healthcare resource utilization related to the patient indication, including medical events and treatments experienced by the patient in the last month.
Measured: At days 30, 60, 90, 120, 150, and 180.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2023
- Study start9 Jan 2023
- Primary completion31 Jul 2025
- Study completion25 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 324 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jamp Pharma Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05913817
- Sponsor's protocol ID
- JAMP-AVT02-001
- Acronym
- EASE PAIN
- Status last verified
- Mar 2026
- First submitted
- 2 Jun 2023
- Last updated
- 17 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Shahrokh DK, Vender RB, Lynde CW, Rao J, Afif W, Steinhart AH, Narula N, Sutton E, Thorne C, Bessette L. Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi(R)) Across Multiple Indications (EASE PAIN). Rheumatol Ther. 2026 Jun;13(3):745-765. doi: 10.1007/s40744-026-00846-1. Epub 2026 Apr 10.
PubMed 41963765
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
- ClinicalTrials.gov ID
- NCT05913817
- Acronym / sponsor ID
- EASE PAIN / JAMP-AVT02-001
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis
- Keywords
- Injection Site Pain
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 324 participants (actual)
- Lead sponsor
- Jamp Pharma CorporationIndustry (pharma, biotech, devices)
- Study start
- 9 Jan 2023 (actual)
- Primary completion
- 31 Jul 2025 (actual)
- Study completion
- 25 Aug 2025 (actual)
- First posted
- 22 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
The phase IV study is an observational, pan-Canadian, multidisciplinary study aiming to enroll 600 patients across 50-70 sites across 3 different Therapeutic Areas (GI, Rheum, Derm).
Detailed description
The current phase 4 study seeks to assess the real-world injection experience, utilization, satisfaction, effectiveness, safety, and tolerability of treatment with AVT-02 (SIMLANDI™) in patients when switching from low-concentration adalimumab Humira® or another adalimumab biosimilar to high-concentration adalimumab SIMLANDI™ for the management of certain gastroenterological (IBD, including CD or UC); rheumatological (including RA, AS, or PsA); or dermatological conditions (including HS or PsO).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Adalimumab Reference Product to AVT-02 | – | Biological: AVT02 (Alvotech Biosimilar to Adalimumab)Patients switching from the high-volume, low concentration, citrate containing Adalimumab reference product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar. |
| Other Adalimumab Biosimilar to AVT-02 | – | Biological: AVT02 (Alvotech Biosimilar to Adalimumab)Patients switching from another high-volume, low concentration, citrate-containing or citrate-free Adalimumab biosimilar product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- To ensure a representative study population, any eligible patient that meets the inclusion/exclusion criteria should be invited to participate in this non-interventional study.
Key inclusion criteria (12 listed)
- Patient aged 18 years or older at the time of consent.
- Patient has been diagnosed with CD, UC, RA, AS, PsA, HS, or PsO for at least 6 months.
- Patient must be a current user of Humira® or another low-concentration adalimumab biosimilar, with treatment initiated at least 6 months prior to screening.
- One of the following:
- Patient must be willing to keep using the same type of injector when switching from their previous adalimumab treatment to SIMLANDI™:
Key exclusion criteria (12 listed)
- Patients previously treated with SIMLANDI™ or another high-concentration adalimumab biosimilar.
- Patients that, in the opinion of the investigator, have any condition that may impair their ability to participate in the study.
- Any current or history of any condition that, in the opinion of the investigator, participation in the study may increase the risk to the patient.
- Patients for whom treatment with adalimumab may be contraindicated (e.g., patients with demyelinating disorders).
- Patients with moderate to severe heart failure, as indicated by New York Heart Association (NYHA) class >= 3.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AVT02 (Alvotech Biosimilar to Adalimumab)Also: HumiraPhase IV Study | Biological | Adalimumab Reference Product to AVT-02, Other Adalimumab Biosimilar to AVT-02 |
Primary outcome
Change from baseline in injection site pain after the first dose of high-concentration adalimumab (AVT-02) as measured by the Visual Analog Scale (VAS); 2 weeks after Humira Injection (can be 1 week for certain indications such as HS).
Time frame: At 2 Weeks
Baseline injection site pain will be defined as the VAS score recorded during the last dose of the low-concentration adalimumab prior to switching to AVT-02.
8 secondary outcomes
Change from baseline in injection site pain after every injection of the high-concentration adalimumab (AVT-02) as measured by VAS during the 180 days of the study.
Time frame: At Every AVT-02 Injection up to 180 Days.
Patient perception of change in injection site pain (5-point Likert) after the first dose of high-concentration adalimumab (AVT-02) compared to Humira® or another low-concentration adalimumab biosimilar.
Time frame: Once a month up to 180 Days.
Distribution of missed doses of AVT-02.
Time frame: At Every AVT-02 Injection up to 180 Days.
Change from baseline in overall satisfaction with the injection (7-point Likert) during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02.
Time frame: At Every AVT-02 Injection up to 180 Days.
Change from baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02.
Time frame: At days 30, 60, 90, 120, 150, and 180.
Change from baseline in physician disease assessment during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02
Time frame: At Baseline and at Day 180.
Change from baseline in patient-reported disease assessment during the 180 days of the study after switching from Humira or another low-concentration adalimumab to AVT-02
Time frame: At Baseline and at Day 180.
Change from baseline in health care utilization during the 180 days of the study.
Time frame: At days 30, 60, 90, 120, 150, and 180.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
- Derived from this study: PubMed 41963765Shahrokh DK, Vender RB, Lynde CW, Rao J, Afif W, Steinhart AH, Narula N, Sutton E, Thorne C, Bessette L. Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi(R)) Across Multiple Indications (EASE PAIN). Rheumatol Ther. 2026 Jun;13(3):745-765. doi: 10.1007/s40744-026-00846-1. Epub 2026 Apr 10.
- Individual participant dataSharing planned: No
Related trials for Crohn Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Crohn Disease and Ulcerative Colitis, run by Jamp Pharma Corporation at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in injection site pain after the first dose of high-concentration adalimumab (AVT-02) as measured by the Visual Analog Scale (VAS); 2 weeks after Humira Injection (can be 1 week for certain indications such as HS). (time frame: At 2 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05913817, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.